Skip to main content
SpringerLink
Log in

Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors

  • Chapter
  • First Online:
Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care

Abstract

Gastric acid acts as a major defense mechanism of the body by sterilizing the contents entering the digestive tract, prevents colonization of bacteria, and helps in digestion. Too much or too little acidic gastric acid is pathologic and can lead to many disorders including peptic ulcer disease, acid reflux, aspiration, pneumonias, and even cancer. Gastric acid secretion is a complex process, and the pharmacological agents which help decrease the pH and volume of gastric acid are antacids, H2 receptor antagonists, and proton pump inhibitors. Gastrointestinal prokinetics are class of drugs that improve small bowel motility and gastric emptying. We will review the pharmacology of antacids, prokinetics, and PPIs in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wolfe MM, Soll AH. The physiology of gastric acid secretion. N Engl J Med. 1988;319:1707–15.

    Article  CAS  PubMed  Google Scholar 

  2. Feldman M. Gastric secretion: normal and abnormal. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Gastrointestinal and liver disease. Philadelphia: Saunders; 1998. p. 587–603.

    Google Scholar 

  3. Zeng N, Athmann C, Kang T, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104:1383–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Dubois A. Control of gastric acid secretion. In: Brandt LJ, editor. Clinical practice of gastroenterology. Philadelphia: Current Medicine; 1999. p. 180–8.

    Google Scholar 

  5. Fordtran JS, Collyns JAH. Antacid pharmacology in duodenal ulcer. Effect of antacids on postcibal gastric acidity and peptic activity. N Engl J Med. 1966;274:92–7.

    Article  Google Scholar 

  6. AHFS drug information. In: Mc Evoy GK, editor. Bethesda: American Society of Health-System Pharmacists; 1998. p. 2374–9.

    Google Scholar 

  7. Littman A, Pine BH. Antacid and anticholinergic drugs. Ann Intern Med. 1975;82:544–15.

    Article  CAS  PubMed  Google Scholar 

  8. Mirrissey JF, Barreras RF. Antacid therapy. N Engl J Med. 1974;290:550–4.

    Article  Google Scholar 

  9. Harvey SC. Gastric antacids and digestants. In: Goodman LS, Gillian A, Gillian AG, editors. The pharmacological basis of therapeutics. 6th ed. New York: Macmillan; 1980. p. 988–1001.

    Google Scholar 

  10. American Society of Anesthesiologists Committee. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011;114(3):495–511.

    Google Scholar 

  11. James CF, Gibbs CP. Nonparticulate antacids. Anesth Analg. 1982;61(9):801.

    Article  CAS  PubMed  Google Scholar 

  12. Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001;119:1222–41.

    Article  CAS  PubMed  Google Scholar 

  13. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997;54:581–96.

    Article  CAS  PubMed  Google Scholar 

  14. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitic. Dig Dis Sci. 1983;28:559–63.

    Article  CAS  PubMed  Google Scholar 

  15. Regan PT, Malagelada JR, DiMagno EP, et al. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med. 1977;297:854–8.

    Article  CAS  PubMed  Google Scholar 

  16. Cousar GD, Gadacz TR. Comparison of antacids on the binding of bile salts. Arch Surg. 1984;119:1018–20.

    Article  CAS  PubMed  Google Scholar 

  17. Clemens JD, Feinstein AR. Calcium carbonate and constipation: a historical review of medical mythopoeia. Gastroenterology. 1977;72:957–61.

    CAS  PubMed  Google Scholar 

  18. Saunders D, Sillery J, Chapman R. Effect of calcium carbonate and aluminum hydroxide on human intestinal function. Dig Dis Sci. 1988;33:409–13.

    Article  CAS  PubMed  Google Scholar 

  19. Strom M. Antacid side-effects on bowel habits. Scand J Gastroenterol. 1982;75(Suppl):54–5.

    CAS  Google Scholar 

  20. Maton PN, Burton ME. Antacids revisited, a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855–70.

    Article  CAS  PubMed  Google Scholar 

  21. Tatro DS. Drug interaction facts. Facts and comparisons. 3rd ed. St Louis; 1992.

    Google Scholar 

  22. Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet. 1984;9:404–34.

    Article  CAS  PubMed  Google Scholar 

  23. Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet. 1977;2:269–80.

    Article  CAS  PubMed  Google Scholar 

  24. Hansten PD, Horn JR, Koda-Kimble MA, et al., editors. Principles of antacid interaction. In: Drug interaction & updates quarterly. Vancouver: Applied Therapeutics, Inc.; 1993. p 69–72.

    Google Scholar 

  25. Hansten PD, Horn JR, Koda-Kimble MA, et al., editors. Antacid drug interactions. In: Drug interaction & updates quarterly. Vancouver: Applied Therapeutics, Inc.; 1993. p 137–51.

    Google Scholar 

  26. Gugler AH. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet. 1990;18:210–9.

    Article  CAS  PubMed  Google Scholar 

  27. Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. Drug Saf. 1995;12:314–33.

    Article  CAS  PubMed  Google Scholar 

  28. Herzog P, Holtermüller KH. Antacid therapy—changes in mineral metabolism. Scand J Gastroenterol Suppl. 1982;75:56–62. [0085-5928] Herzog.

    CAS  PubMed  Google Scholar 

  29. McMillan DE, Freeman RB. The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition. Medicine. 1965;44:485–501.

    Article  CAS  PubMed  Google Scholar 

  30. Merwat SN, Spechler SJ. Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol. 2009;104:1897–902.

    Article  CAS  PubMed  Google Scholar 

  31. Canani RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol. 2010;26:31–5.

    Article  PubMed  Google Scholar 

  32. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137.

    Article  CAS  PubMed  Google Scholar 

  33. Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:599.

    Article  CAS  PubMed  Google Scholar 

  34. Loftus CG, Harewood GC, Baron TH. Assessment of predictors of response to neostigmine for acute colonic pseudo-obstruction. Am J Gastroenterol. 2002;97:3118–22.

    Article  CAS  PubMed  Google Scholar 

  35. Holte K, Kehlet H. Postoperative ileus: progress towards effective management. Drugs. 2002;62(18):2603–15.

    Article  CAS  PubMed  Google Scholar 

  36. Hallerbäck B, Ander S, Glise H. Effect of combined blockade of beta-adrenoceptors and acetylcholinesterase in the treatment of postoperative ileus after cholecystectomy. Scand J Gastroenterol. 1987;22(4):420–4.

    Article  PubMed  Google Scholar 

  37. Maher L, Young PJ. Cardiac arrest complicating neostigmine use for bowel opening in a critically ill patient. Crit Care Resusc. 2011;13(3):192–3.

    PubMed  Google Scholar 

  38. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther. 1993;7:5–20.

    Article  CAS  PubMed  Google Scholar 

  39. Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med. 1983;98:86–95.

    Article  CAS  PubMed  Google Scholar 

  40. McCallum RW. Clinical pharmacology forum: motility agents and the gastrointestinal tract. Am J Med Sci. 1996;312:19–26.

    Article  CAS  PubMed  Google Scholar 

  41. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004;44:661–5.

    Article  Google Scholar 

  42. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6:463–7.

    Article  CAS  PubMed  Google Scholar 

  43. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet. 1983;8(6):523–9.

    Article  CAS  PubMed  Google Scholar 

  44. Walker M, Samii A. Chronic severe dystonia after single exposure to antiemetics. Am J Emerg Med. 2006;24:125–7.

    Article  PubMed  Google Scholar 

  45. McCallum RW, Sowers JR, Hershman JM, Sturdevant RAL. Metoclopramide stimulates prolactin secretion in man. J Clin Endocrinol Metab. 1976;42:1148–52.

    Article  CAS  PubMed  Google Scholar 

  46. Edwards M, Koo MW, Tse RK. Oculogyric crisis after metoclopramide therapy. Optom Vis Sci. 1989;66:179–80.

    Article  CAS  PubMed  Google Scholar 

  47. Nonino F, Campomori A. Neuroleptic malignant syndrome associated with metoclopramide. Ann Pharmacother. 1999;33(5):644–5.

    Article  CAS  PubMed  Google Scholar 

  48. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–9.

    Article  CAS  PubMed  Google Scholar 

  49. Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379–84.

    Article  CAS  PubMed  Google Scholar 

  50. Reddymasu SC M.D., Soykan I M.D., McCallum RW M.D. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036–45.

    Article  CAS  PubMed  Google Scholar 

  51. Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin N Am. 1989;18:437–57.

    CAS  Google Scholar 

  52. Weber Jr FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastro intestinal prokinetic agent. Am J Gastroenterol. 1993;88(4):485–90.

    CAS  PubMed  Google Scholar 

  53. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;18:CD001960.

    Google Scholar 

  54. Karamanolis G, Tack J. Promotility medications—now and in the future. Dig Dis. 2006;24:297–307.

    Article  CAS  PubMed  Google Scholar 

  55. Itoh Z. Motilin and clinical application. Peptides. 1997;18:593–608.

    Article  CAS  PubMed  Google Scholar 

  56. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil. 2005;17:643–53.

    Article  CAS  PubMed  Google Scholar 

  57. Camilleri M, et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 2013;108:18–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56:1–18.

    Article  PubMed  Google Scholar 

  59. Drici MD, Knollmann BC, Wang WX, Woosley RL. Cardiac actions of erythromycin: influence of female sex. JAMA. 1998;280:1774–6.

    Article  CAS  PubMed  Google Scholar 

  60. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis. 2002;35:197–200.

    Article  PubMed  Google Scholar 

  61. Berthet S, Charpiat B, Mabrut JY. Erythromycin as a prokinetic agent: risk factors. J Visceral Surg. 2010;147:e13–8.

    Article  CAS  Google Scholar 

  62. Thompson JS M.D., Quigley EMM M.D. Prokinetic agents in the surgical patient. Am J Surg (Omaha, NE). 1999;177:508–14.

    Article  CAS  Google Scholar 

  63. Mercadante S, Porzio G. Octreotide for malignant bowel obstruction: twenty years after. Crit Rev Oncol Hematol. 2012;83(3):388–92.

    Article  PubMed  Google Scholar 

  64. Owyang C. Octreotide in gastrointestinal motility disorders. Gut. 1994;35 Suppl 3:S11–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. NEJM. 1991;325:1461–7.

    Article  CAS  PubMed  Google Scholar 

  66. Gunshefski LA, Rifley WJ, Slattery DW, et al. Somatostatin stimulation of the normal esophagus. Am J Surg. 1992;163:59–62.

    Article  CAS  PubMed  Google Scholar 

  67. Cullen JJ, Eagon C, Dozois EJ, Kelly KA. Treatment of acute postoperative ileus with octreotide. Am J Surg. 1993;165:113–20.

    Article  CAS  PubMed  Google Scholar 

  68. Waller SL. Prostaglandins and the gastrointestinal tract. Gut. 1973;14(5):402–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  69. Soffer EE, Launspack J. Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans. Dig Dis Sci. 1993;18:851–5.

    Article  Google Scholar 

  70. Bassotti G, Bucaneve G, Furno P, et al. Double blind, placebo controlled study on the effects of diclofenac sodium and indomethacin on postprandial gastric motility in man. Dig Dis Sci. 1998;42:1172–6.

    Article  Google Scholar 

  71. Kapoor S. Lubiprostone: clinical applications beyond constipation. World J Gastroenterol. 2009;15(9):1147–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  72. Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung EZ, Lee K, Sanger GJ. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008;154:126–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11(5):841–50.

    Article  CAS  PubMed  Google Scholar 

  74. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16 Suppl 2:17–28.

    Article  PubMed  Google Scholar 

  75. Neyens R, Jackson KC. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. J Pain Palliat Care Pharmacother. 2007;21:27–33.

    Article  PubMed  Google Scholar 

  76. Lambert R. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1997;11:651–62.

    Article  CAS  PubMed  Google Scholar 

  77. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–96.

    Article  CAS  PubMed  Google Scholar 

  78. Lanza FL, Chan FK, Quigley EM, Practice parameters committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104:728–38.

    Article  PubMed  Google Scholar 

  79. Chubineh S M.D., Birk J M.D. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012;105(11):613–8.

    Article  PubMed  Google Scholar 

  80. Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger–Ellison syndrome. Expert Opin Pharmacother. 2009;10(7):1145–57.

    Article  CAS  PubMed  Google Scholar 

  81. Neena S. Abraham, proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol. 2012;28:615–20.

    Article  Google Scholar 

  82. Jefferies KC, Cipriano DJ, Forgac M. Function, structure and regulation of the vacuolar (H+)-ATPases. Arch Biochem Biophys. 2008;476:33–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  83. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol. 2012;46:93–114.

    Article  PubMed  Google Scholar 

  84. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastro esophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4:50–4.

    Article  CAS  PubMed  Google Scholar 

  85. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–22.

    Article  CAS  PubMed  Google Scholar 

  86. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–8.

    Article  PubMed  Google Scholar 

  87. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.

    Article  CAS  PubMed  Google Scholar 

  88. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol. 2012;9:132–9.

    Article  CAS  PubMed  Google Scholar 

  89. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26:545–53.

    Article  CAS  PubMed  Google Scholar 

  90. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Eng J Med. 2006;355:1834–6.

    Article  CAS  Google Scholar 

  91. Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009;151:755–6.

    Article  PubMed  Google Scholar 

  92. Dornebal J, Bijlsma R, Brouer RML. An unrecognized potential side effect of proton pump inhibitors: hypomagnesaemia. Ned Tidjschr Geenesk. 2009;153:A711.

    Google Scholar 

  93. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors – a review. Neth J Med. 2009;67:169–72.

    CAS  PubMed  Google Scholar 

  94. Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56:112–6.

    Article  PubMed  Google Scholar 

  95. Regolisti G, Cabassi A, Parenti E, et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56:168–74.

    Article  PubMed  Google Scholar 

  96. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010;103:387–95.

    Article  CAS  PubMed  Google Scholar 

  97. Shabajee N, Lamb EJ, Sturgess I, et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a42.

    Article  Google Scholar 

  98. Administration US FDA. FDA Drug Safety Communication: low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). 2011. http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm.

  99. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256–60.

    Article  CAS  PubMed  Google Scholar 

  100. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol. 2008;52:1038–9.

    Article  PubMed  Google Scholar 

  101. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713–8.

    Article  PubMed Central  PubMed  Google Scholar 

  102. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.

    Article  CAS  PubMed  Google Scholar 

  103. Yeo C. Shackelford’s surgery of the alimentary tract. 6th ed. Philadelphia: WB Saunders; 2007.

    Google Scholar 

  104. Townsend CM. Sabiston textbook of surgery. 19th ed. Philadelphia: Saunders Elsevier; 2012.

    Google Scholar 

  105. Brenner GM. Pharmacology. 4th ed. Philadelphia: Saunders Elsevier; 2012.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Perioperative Medicine, University of Louisville School of Medicine, 530 S Jackson Street RM C2A01, Louisville, KY, 40202, USA

    Sunitha Kanchi Kandadai MD & Mark V. Boswell MD, PhD, MBA

Authors
  1. Sunitha Kanchi Kandadai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark V. Boswell MD, PhD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunitha Kanchi Kandadai MD .

Editor information

Editors and Affiliations

  1. Departments of Anesthesiology and Pharmacology, LSU Health Sciences Center, New Orleans, Louisiana, USA

    Alan David Kaye

  2. Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, Stockton, California, USA

    Adam M. Kaye

  3. Center for Perioperative Management and Medical Informatics, Brigham and Women’s Hospital, Boston, Massachusetts, USA

    Richard D. Urman

Chemical Structures

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kandadai, S.K., Boswell, M.V. (2015). Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors. In: Kaye, A., Kaye, A., Urman, R. (eds) Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8948-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8948-1_21

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8947-4

  • Online ISBN: 978-1-4614-8948-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation